SBIR/STTR Research Award

Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture

Award identifier 3fd2ba05581166ff5049e4712d7a39cf48b02b3692fbc75bbc135edd0092d58cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$175,849

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CHEMOSEN3D INC
Proposal award date
2018-02-01
Contract end date
2020-01-31
UEI
LH32V6UMM1K5
Solicitation number
PA16-303
Topic code
NIAID

Research abstract

Project Summary Adoptive immunotherapy trials using genetically modified natural killerNKand T cells with redirected specificity against B cell malignancies have demonstrated therapeutic efficacyTwo early phase clinical trials have been initiated at The University of Texas MDAnderson Cancer Center to evaluate the safety and efficacy of adoptive transfer of autologous and allogeneic T cells expressing a CDspecific chimeric antigen receptorCARinto patients with advanced B cell malignanciesThese CDspecific CART cells are selectively propagated in vitro in the presence of irradiated artificial antigen presenting cellsaAPCexpressing co stimulatory molecules that sustain their proliferation to clinically sufficient numbers in compliance with current good manufacturing practicecGMPfor Phase I II trialsThis conventional culturing process requiresdays to generate the required andgtCART cells for each infusionReduction of the time required to generate clinically sufficient numbers in tissue culture will reduce manufacturing costs significantly and will yield a clinical product in which the CART cells have increased replicative potential and are less differentiatedTo enhance the production processwe propose to develop novel co culture protocol that utilizes magnetic co levitation to increase the contact interface between CARNK or T cells and the stimulating aAPCs to significantly improve the kinetics of numeric expansion of CARlymphocytes with desired specificity and preservation of memory phenotypeOur long term goal is to develop a cGMP compliant protocol based on three dimensionalDmagnetic levitation co cultures for the rapid and specific production of CART and NK cells to support ongoing immunotherapy trialsOur novel expansion method is based on the central hypothesis that increasing the number and duration of contact points between CART or NK cells and aAPCs will accelerate the proliferation of the targeting cellsyielding clinically sufficient number of cells in less timeIn this Phase I SBIR proposalwe aim to develop and optimizeD cell magnetic levitation co culture conditions to improve the propagation of CART cells by magnetic nanoparticle labeling of aAPCsNKand T cells and co culturing inD to maximize expansion of the genetically modified CDspecific NK and T cellsDevelopment of this expansion methodology will significantly impact the treatmentmanagementand cost of adoptive cell therapies of B cell malignancies Narrative Adoptive T cell therapy offers a promising approach for treating B cell malignanciesThe process of preparing these targeting T cells for transplantation involves isolation of antigen specific cells and expansion in vitro in the presence of target antigenThe process of preparing these cells is lengthytaking up todaysIt is recognized that reducing the preparation time in culture will save manufacturing costs will yield less differentiated T cells that have increased targeting potentialThe proposed work will implement and optimize T cell expansion methods that are based on magnetically levitated cell cultures to produce clinically sufficient number of T cells in one third of the time required to manufacture by conventional methods

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2010–2018). Reported award amounts total $2,215,805. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.